Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

July 26, 2023 updated by: Jacqueline K Limberg, PhD, University of Missouri-Columbia
Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Missouri
      • Columbia, Missouri, United States, 65211
        • University of Missouri

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • healthy,
  • type 2 diabetes
  • BMI 18-40 kg/m2,
  • non-pregnant,
  • non-breastfeeding,
  • non-nicotine users.

Exclusion Criteria:

  • cardiovascular disease including myocardial infarction, heart failure, coronary artery disease, stroke;
  • renal or hepatic diseases;
  • active cancer;
  • autoimmune diseases;
  • immunosuppressant therapy;
  • excessive alcohol consumption (>14 drinks/week);
  • current nicotine use;
  • foot ulcers;
  • diabetic neuropathy;
  • medication directly influencing sympathetic nervous system activity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Oral Glucose Tolerance Test
Subjects will consume a 75 g glucose drink within 1-min and monitored for 2 hours.
Other: Hyperoxia Exposure
2 hours of hyperoxia exposure during OGTT
Other: Normoxia Exposure
2 hours of normoxia exposure during OGTT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Glucose change in response to OGTT
Time Frame: 2 hours post glucose ingestion
2 hours post glucose ingestion
Insulin change in response to OGTT
Time Frame: 2 hours post glucose ingestion
2 hours post glucose ingestion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Missouri-Columbia

Investigators

  • Principal Investigator: Jacqueline Limberg, Ph.D., University of Missouri-Columbia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 9, 2020

Primary Completion (Actual)

May 10, 2023

Study Completion (Actual)

May 10, 2023

Study Registration Dates

First Submitted

January 21, 2022

First Submitted That Met QC Criteria

January 21, 2022

First Posted (Actual)

February 2, 2022

Study Record Updates

Last Update Posted (Actual)

July 27, 2023

Last Update Submitted That Met QC Criteria

July 26, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2018486

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes

Clinical Trials on Hyperoxia Exposure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe